Melissa Hardesty, MD, MPH, Discusses the Focus of the 2021 Society of Gynecologic Oncology Annual Meeting

Article

Hardesty detailed her expectations for the focus of the conference and the exciting topical opportunities presented this year’s SGO Annual Meeting compared with past years.

Melissa Hardesty, MD, MPH, of the Alaska Women’s Cancer Care, spoke with CancerNetwork® regarding topics of discussion at the forefront of this year’s Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women’s Cancer.

Transcription:

This year, the meeting has focused on diversity and inclusiveness [by] really looking at some actual research about how these things impact our patients, how they impact our providers, racial bias, and all of that. There’s a lot of content that’s specifically trying to help us learn how to do better in these ways, to just continue on further conversations. I know that the program organizers have put a strong emphasis on that. There [are] exciting talks in the opening plenary that I think in meetings past might not have been selected for [presentation, and] focusing on the commitment to that area.

Recent Videos
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Related Content